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and degrading enzymes, Aβ transport receptors, and AD-
type pathologies including hyperphosphorylated tau, neu-
roinflammation, as well as neuronal degeneration and loss 
in the brains of parabiotic AD mice. Our study revealed 
that the peripheral system is potent in clearing brain Aβ and 
preventing AD pathogenesis. The present work suggests 
that peripheral Aβ clearance is a valid therapeutic approach 
for AD, and implies that deficits in the Aβ clearance in the 
periphery might also contribute to AD pathogenesis.
Keywords Alzheimer’s disease · Parabiosis · Amyloid-
beta · Clearance · Liver · Kidney · Periphery
Introduction
Alzheimer’s disease (AD) is the most common form of 
dementia among the elderly. Senile plaques containing 
amyloid-beta protein (Aβ) in the brain are a pathological 
hallmark of AD and they play a pivotal role in AD patho-
genesis. The steady-state level of Aβ in the brain is deter-
mined by the balance between Aβ production and its clear-
ance [47]. In the brain, Aβ can be cleared via microglial 
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phagocytosis and proteolytic degradation by enzymes such 
as neprilysin (NEP) and insulin-degrading enzyme (IDE) 
[47]. Transport of Aβ from the brain into the peripheral 
blood has been demonstrated in both animal models and 
humans [28, 36]. There are several potential pathways for 
the efflux of brain Aβ into the periphery. These include 
transport across the blood–brain barrier (BBB) mediated by 
low-density lipoprotein receptor-related peptide 1 (LRP1) 
[39], drainage from interstitial fluid (ISF) into cerebrospi-
nal fluid (CSF) via perivascular [35] or glymphatic path-
ways [15], reabsorption from CSF into the venous blood 
via arachnoid villi [40] and blood–CSF barrier [32], or into 
the lymphatic system from the perivascular and perineu-
ral spaces [15, 34], and possibly via meningeal lymphatic 
vessels [15, 27] (see review in [41]). However, whether 
brain-derived Aβ is physiologically catabolized in the 
peripheral tissues and organs, and the therapeutic potential 
of this peripheral Aβ catabolism for AD, remains largely 
unknown. In the present study, we investigated the physio-
logical catabolism of brain-derived Aβ in the periphery, and 
examined its therapeutic potential for AD using a model of 
parabiosis between transgenic AD mice and their wild-type 
littermates.
Materials and methods
Participants and blood sampling
The human study was approved by the Institutional Review 
Board of Daping hospital affiliated to Third Military Medi-
cal University. Informed consent was obtained from all indi-
vidual participants included in the study. This study recruited 
30 patients with atrioventricular reentrant tachycardia (AVRT) 
(left accessory pathways) who underwent radiofrequency 
catheter ablation (RFCA). Participants had an average age 
of 49.5 years (19–74 years) and included 17 males and 13 
females, without cognitive impairment or dementia based on 
the clinical assessment. To measure the catabolism of Aβ in the 
periphery, we used time-matched arterial and venous peripheral 
blood samples as described previously [36]. Once the patients 
were deemed to undergo RFCA, catheters were placed in the 
left subclavian vein (SV), right femoral vein (FV), and right 
femoral artery (FA) simultaneously. Blood was collected from 
superior vena cava (SVC), inferior vena cava (IVC) proximal to 
hepatic vein (HV), the right FV and FA within 5 min (Fig. 1b). 
Five milliliters of blood were collected in vacuum blood tubes 
with anticoagulants at each site from the catheters. Blood was 
placed on ice immediately after sampling, and plasma was sep-
arated within 2 h and stored in polypropylene eppendorf tubes 
at −80 °C for further use. To avoid the influence of diurnal 
changes of Aβ levels, all the blood sampling were performed 
between 8:30 and 9:30 in the morning.
In a parallel animal study, the APPswe/PS1dE9 mouse 
model of AD (AD mice, Jackson Laboratories, Bar Har-
bor, MA) was used. This mouse model harbors the human 
amyloid precursor protein (APP) gent containing Swed-
ish mutant and human presenilin 1 (PS1) gene encod-
ing the deleted exon 9 mutation under control of mouse 
PrP promoter which directs the transgene expression pre-
dominantly in brain neurons [18], and develops amyloid 
plaques at 6 months of age [17]. Blood was sampled from 
the jugular vein (JV), abdominal aorta (AA), and posterior 
vena cava (PVC) of female APPswe/PS1dE9 mice aged 
6 months (n = 10) following approval by the Third Mili-
tary Medical University Animal Welfare Committee. Blood 
was sampled within 5 min at each site. The sampling was 
performed during 8:30–9:30 in the morning. Blood samples 
were examined for Aβ40 and Aβ42 levels following our 
protocols as described previously [3].
Analysis for biodistribution of 125I‑Aβ1‑40
The radiolabelling of Aβ1-40 was performed following 
previous protocols [8]. Synthetic Aβ1-40 was iodinated 
with Na125I (specific activity 37 MBq/mg, China Institute 
of Atomic Energy) using the Iodogen technique (Pierce). 
Radioiodinated Aβ1-40 was separated from free iodine 
using a size exclusion column (Sephadex G-25, Pharma-
cia). The specific activity of radioiodinated Aβ1-40 was 
1.065 MBq/μg. The radiochemical purity was >95 % 
trichloroacetic acid-precipitable.
Three-month-old male C57BL/6J mice received a bolus 
injection with 6.9 MBq 125I-Aβ in 0.3 ml of lactate Ring-
er’s solution (6 g/L NaCl, 0.2 g/L CaCl2, 3.1 g/L sodium 
lactate, 0.3 g/L KCl, pH 7.1) via the tail vein (n = 8). 
Mice were sacrificed by overdose of ketamine at 120 min 
after injection. The brain, skin, gastrointestinal tract, lung, 
heart, liver, spleen, kidney, and carcass were collected and 
weighted. The radioactivity (CPM values) of samples was 
measured with a wipe test counter (CAPRAC), and the 
resulting counts/min was normalized per gram of tissue. 
The radioactivity values are shown as % of total radioactiv-
ity or counts/min/gram of tissue.
Parabiosis
APPswe/PS1dE9 transgenic (Tg) mice were bred in the 
animal facility of Daping hospital. All mouse husbandry 
procedures were approved by the Third Military Medi-
cal University Animal Welfare Committee. To exclude the 
influence of gender on brain Aβ deposition, female Tg 
mice were used in the present study. Each pair of mice was 
placed together in a cage for 1 month to allow the mice 
to adapt to each other [10, 11]. Female Tg mice and their 
age- and weight-matched female wild-type (Wt) littermates 
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were selected for parabiosis including the parabiosis from 
3-months of age to 9-months of age (as the group before Aβ 
deposition in the brain) and the parabiosis from 9-months 
of age to 12-months of age (as the group after Aβ depo-
sition in the brain) (n = 8 per group). The age-matched 
female Wt (n = 8) and Tg mice (n = 8) without parabiosis 
were used in parallel as controls. The parabiosis was per-
formed following procedures as previously described [31]. 
Briefly, animals were anesthetized with ketamine (100 mg/
kg), xylazine (20 mg/kg), and acepromazine (3 mg/kg), 
and placed in a parallel orientation. A left lateral incision 
was made on one mouse while a right one was made on the 
partner mouse, extending from the base of the ear toward 
the hip. The incision included skin and muscle along thorax 
and abdomen. The opposing muscle layers of the two mice 
were joined with 5-0 silk sutures. The scapulae of the mice 
were fixed together with 4-0 silk sutures. The correspond-
ing dorsal and ventral skin was sutured with 4-0 silk. After 
the surgery, the parabiotic mice were allowed to recover in 
a warm and clean environment before being transferred into 
the husbandry area. Prophylactic antibiotic treatment (enro-
floxacin, 5 mg/kg) was started 1 day prior to the surgery 
and continued for 1 week. All animals received analgesic/
anti-inflammatory treatment (acetylsalicylic acid 5 mg/kg) 
for 2 weeks.
Brain sampling
Animals were euthanized by overdosing with pentobarbi-
tal (0.08 g/kg). Blood was sampled from the right atrium 
of the heart, followed by intracardial perfusion with 100 ml 
of 0.1 % NaNO2 in phosphate buffer. Brains were sam-
pled and weighed. Left hemispheres were fixed in 4 % 
paraformaldehyde for histological analysis, and right hemi-
spheres were snap frozen in liquid nitrogen and stored at 
−80 °C for biochemical analysis.
Fig. 1  Aβ concentrations at different locations of the systemic circu-
lation. a The venous/arterial (V/A) ratio of Aβ concentrations among 
blood samples from different venous locations in humans (n = 30). 
The blue dotted line represents Aβ concentration in the femoral artery 
(FA) as a reference. b A diagram of the circulation system and sam-
pling locations for Aβ measurement. The superior vena cava (SVC) 
collects blood from the head containing brain-derived Aβ. The infe-
rior vena cava (IVC) proximal to the hepatic vein (HV) collects blood 
from the lower part of the body including liver, kidney, and gastro-
intestinal tract. The femoral vein (FV) contains metabolites after the 
circulation through the lower limbs. The femoral artery (FA) contains 
blood virtually identical to that in the aorta and is used as a reference. 
c The venous/arterial (V/A) ratio of Aβ concentrations among blood 
samples from different locations in APPswe/PS1 mice (n = 10). The 
blue dotted line represents the Aβ concentration in abdominal aorta 
(AA) as a reference. CA carotid artery, PV portal vein, JV jugular 
vein, SVC superior vena cava, IVC inferior vena cava, HV hepatic 
vein, FV femoral vein, FA femoral artery, PVC posterior vena cava. 
Mean ± SEM, one-way ANOVA and Tukey’s test for human plasma 
and 2-tailed t test for mouse plasma, *P < 0.05, **P < 0.01. N.S. no 
statistical significance
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Histology and quantification
Coronal sections of the brain were cut at a 35 μm thick-
ness with a cryosectioning microtome and stored at 4 °C in 
PBS containing 0.1 % sodium azide until use. For the his-
tology analysis, a series of five equally spaced tissue sec-
tions (~1.3 mm apart) spanning the entire brain were used 
for each type of staining.
Aβ plaques
The compact Aβ plaques were visualized with Congo red 
staining following our previous protocols [51]. In brief, 
sections were treated with working sodium chloride solu-
tion (containing sodium chloride saturated in 80 % alco-
hol and 0.01 % sodium hydroxide) at room temperature 
(RT) for 20 min, then placed directly into working Congo 
red solution (containing saturated Congo red in work-
ing sodium solution) for 1 h, and then dehydrated rapidly 
in absolute alcohol. The total Aβ plaques containing both 
compact and diffuse plaques were visualized with antibody 
6E10 immunohistochemistry.
Cerebral amyloid angiopathy (CAA)
Cerebral amyloid angiography (CAA) were visualized with 
Congo red staining and quantified following previously 
described protocols [48]. In brief, sections were stained 
with Congo red and images were collected at the selected 
regions from frontal cortex to hippocampus of each mouse 
brain under the same illumination conditions. Quantifi-
cation of Congo red staining was performed using the 
Image J software. A series of standard images representing 
extremes of high and low levels of Congo red staining were 
used to establish segmentation threshold using the RGB 
method to distinguish positively stained pixels. CAA was 
manually selected from each image, and the measurement 
of positively stained pixels was performed under the same 
RGB segmentation values. This yields the amyloid load 
due to Congo red staining of blood vessels. Meanwhile, the 
average number of CAA profiles per section was calculated 
by dividing the total count of CAA with the total number of 
sections as in our previous study [50].
Microhemorrhage
Sections were stained for hemosiderin with 2 % potassium 
ferrocyanide in 2 % hydrochloric acid for 15 min, followed 
by a counterstaining with 1 % Neutral Red solution for 
10 min at room temperature [51]. Microhemorrhage pro-
files were counted under microscopy, and the average num-
ber of hemosiderin deposits per section was calculated.
Neuronal degeneration
Apoptosis of neuronal cells was detected with NeuN and 
Caspase-3 double immunofluorescence staining. Neuronal 
loss and neurite degeneration were detected with NeuN and 
microtubule-associated protein (MAP)-2 double immuno-
fluorescence staining.
Astrocytosis and microgliosis
Immunohistochemistry was used to visualize astrocyto-
sis and microgliosis with anti-CD45 antibody to detect 
activated microglia and anti-glial fibrillary acidic protein 
(GFAP) antibody to detect astrocytes.
Quantification was conducted by an investigator who 
was blinded to the group information of the samples. The 
area fraction and/or density of positive staining was quanti-
fied with ImageJ software.
ELISA assays
Frozen brain was homogenized in liquid nitrogen and suc-
cessively extracted with TBS, 2 % SDS, and 70 % formic 
acid solutions following our previous protocols [51]. Lev-
els of Aβ40 and Aβ42 were measured using ELISA kits 
(Covance). Concentrations of inflammatory cytokines IL-6, 
IL-1β and TNF-α in brain extracts and blood were quanti-
tatively measured with ELISA according to the manufac-
turer’s instructions (eBioscience).
Western blotting
The levels of molecules or enzymes involving Aβ metabo-
lism, phosphorylated Tau, and synapse-related proteins 
were analyzed using Western blotting. Proteins in the ani-
mal brain homogenate were extracted with RIPA buffer. 
Samples were loaded on SDS-PAGE (4–10 % acrylamide) 
gels. Separated proteins were transferred to nitrocellulose 
membranes. The blots were probed with the following anti-
bodies: anti-APP C-Terminal (171610, Millipore) which 
recognizes full-length APP (APPfl) and C-terminal frag-
ment (CTF)-β, anti-BACE1 (Millipore), anti-NEP (Mil-
lipore), anti-receptor for advanced glycosylation prod-
ucts (RAGE, Millipore), anti-LRP-1 (5A6, Calbiochem), 
anti-IDE (Epitomics), anti-phosphorylated-Tau antibodies 
including anti-pS396 (Signalway) and anti-pS199 (epitom-
ics), anti-Synaptophysin (Millipore), anti-Synapsin-1 (Mil-
lipore), anti-PSD95 (Millipore), anti-PSD93 (Millipore) 
and anti-β-actin (Sigma-Aldrich). The membranes were 
incubated with IRDye 800CW secondary antibodies (Li-
COR) and scanned using the Odyssey fluorescent scanner. 
The band density was normalized to β-actin for analysis.
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Statistical analysis
All data represent the mean ± SEM. Statistical analy-
sis included 2-tailed Student’s t test for the comparison 
of two groups, one-way ANOVA and Tukey’s test for the 
comparison of multiple groups when required. Normality 
and equal-variance testing was performed for all assays. 
P < 0.05 was considered significant. All analyses were 
completed with SPSS software, version 10.0.
Results
Aβ levels in different locations of the circulation
A recent study in humans demonstrates the efflux of 
Aβ from the brain to the plasma [36]. However, the fate 
of brain-derived Aβ in the periphery remains unclear. 
To examine the catabolism of brain-derived Aβ in the 
periphery, we measured Aβ levels in the different parts 
of the circulation including: (a) the superior vena cava 
which collects blood from the head containing brain-
derived Aβ, (b) the inferior vena cava proximal to the 
hepatic vein which collects blood from the lower part 
of the body including liver, kidney and gastrointesti-
nal tract, (c) the femoral vein which contains metabo-
lites after the circulation through the lower limbs, and 
(d) the femoral artery which contains blood virtually 
identical to that in the aorta and used as a reference 
(Fig. 1b, Supplemental Table 1). In addition, Aβ levels 
in blood from the jugular vein, the abdominal aorta and 
the posterior vena cava were examined in AD mice aged 
6 months (Supplemental Table 2). The Aβ concentrations 
in different locations of the circulation were divided by 
time-matched arterial Aβ concentrations to generate the 
venous/arterial (V/A) ratio. We found that V/A ratios of 
Aβ40 and total Aβ from the superior vena cava were sig-
nificantly higher than that from the inferior vena cava 
in humans (Fig. 1a), and V/A ratios of Aβ40 and total 
Aβ from the jugular vein of AD mice were also higher 
than that from the posterior vena cava (Fig. 1c). Interest-
ingly, V/A ratios of Aβ40 and total Aβ from the inferior 
vena cava were significantly lower than that from the 
femoral vein in humans (Fig. 1a). These findings suggest 
that brain-derived Aβ in the arterial blood is physiologi-
cally cleared when it goes through the capillary beds of 
the peripheral organs and tissues, and that the internal 
organs remove significant amounts of arterial Aβ. There 
were no differences in Aβ42 concentrations among dif-
ferent locations of the circulation in both humans and 
AD mice (Fig. 1a, c), suggesting that Aβ42 is not a sen-
sitive marker to reflect peripheral Aβ catabolism possi-
bly due to its low level in blood [36].
Distribution of 125I‑Aβ1‑40 in peripheral tissues 
and organs
We next investigated where Aβ is metabolized in the 
periphery in wild-type mice. Two hours after intravenous 
(i.v.) bolus injection of 125I labeled Aβ through the tail vein 
different organs and tissues were collected and weighed. 
In addition, radioactivities were detected respectively fol-
lowing a previous protocol [8]. We found that the injected 
radioactivity was located mostly in the liver, kidney, gas-
trointestinal tract, and skin while the rest was located in the 
carcass (Supplemental Fig. 1a). Moreover, by normalizing 
the data according to the mouse weights, we also observed 
significant amounts of radioactivity uptake in the liver, kid-
ney, gastrointestinal tract, and skin but little in the carcass 
(Supplemental Fig. 1b). The radioactivity uptake in the 
brain accounted for only 1.67 % of total injected radioac-
tivity, suggesting that peripheral organs and tissues are the 
main places of Aβ clearance in the periphery. This is par-
ticularly true for the liver and kidney, which are suggested 
to be the major organs for uptake of exogenous Aβ in the 
blood [8].
Parabiosis reduces brain amyloid deposition
The above findings raise a critical question of whether the 
clearance of Aβ by the peripheral system has any impact on 
the pathogenesis of AD. We utilized isochronic parabiosis to 
test the efficacy of peripheral clearance of Aβ in alleviating 
the amyloid burden in the brains of APPswe/PS1dE9 trans-
genic mice. After parabiosis between transgenic and wild-
type mice, the circulation of the parabionts was connected so 
that Aβ species in the blood of the parabiotic transgenic mice 
could be transported into the wild-type mice. Thus, the trans-
genic mice acquired an additional peripheral system from 
wild-type mice. This model provided a reliable approach to 
test the Aβ clearing capacity of the peripheral system.
Parabiosis was performed before Aβ deposition at 
3 months of age and samples were collected for analy-
sis after Aβ deposition at 9 months of age (Supplemental 
Fig. 2a). After parabiosis, the blood levels of both Aβ40 
and Aβ42 of the parabiotic transgenic mice [pa(3-9mon)
Tg] were significantly lower than that of the control trans-
genic mice (Supplemental Fig. 2b). Additionally, blood 
Aβ levels of the parabiotic wild-type mice [pa(3-9mon)
Wt mice] were comparable to that of pa(3-9mon)Tg mice. 
These findings suggest that Aβ from the pa(3-9mon)Tg 
mice entered the circulation of the pa(3-9mon)Wt mice.
Compared with control transgenic mice, pa(3-9mon)Tg 
mice had dramatic reductions in area fraction and plaque 
density of both compact plaques stained with Congo red, 
total plaques stained with 6E10 in neocortex and hip-
pocampus (Fig. 2a–d), Aβ deposition in vessel walls (CAA) 
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(Fig. 2h–j), and microbleed profiles (Supplemental Fig. 3). 
The total area fraction of amyloid deposition in both hip-
pocampus and neocortex was reduced by 70 % for Congo 
red positive plaques, and 86 % for 6E10 positive plaques 
in pa(3-9mon)Tg mice relative to control transgenic mice 
(Fig. 2b, d). After parabiosis, the levels of Aβ40 and Aβ42 
were significantly reduced in the brain homogenates of 
pa(3-9mon)Tg mice in comparison with control transgenic 
mice, with a reduction of total Aβ by 68 % (Fig. 2e–g). 
These data suggest that providing an additional peripheral 
system by parabiosis can substantially prevent Aβ deposi-
tion in the brain of transgenic mice.
We further investigated whether enhancement of periph-
eral Aβ clearing capacity could reduce Aβ burden after 
extensive Aβ deposition in the brain using the parabiosis 
models between 9-month-old female transgenic and age-
matched female wild-type mice. Similarly, after 3 month 
parabiosis, the Congo red and 6E10-positive Aβ plaque bur-
dens in the neocortex in pa(9-12mon)Tg mice were signifi-
cantly lower than that of 12 months old transgenic control, 
and there was no significant increase in Aβ plaque burdens 
in pa(9-12mon)Tg mice when compared with 9-month-old 
transgenic mice (Supplemental Fig. 4). Taken together, our 
findings suggest that enhancing Aβ clearance in the periph-
ery has both preventive and treatment potential for AD.
As the amyloid burden is associated with both Aβ pro-
duction and clearance, we further investigated the metab-
olism of APP after parabiosis. There were no significant 
differences in the levels of full-length APP (APPfl), C-ter-
minal fragment (CTF)-α, CTF-β, beta-secretase (BACE)-
1, Aβ-degrading enzymes IDE and NEP, and Aβ transport 
receptors across BBB (LRP-1 and RAGE) in the brain 
between the pa(3-9mon)Tg mice and the control transgenic 
mice (Supplemental Fig. 5), suggesting that the reduction 
of brain Aβ burden after parabiosis was not due to changes 
in Aβ production or degradation. In addition, as the parabi-
otic mice were of the same age, the reduced brain Aβ bur-
den was not due to the rejuvenation mechanism as observed 
in a previous parabiosis study [42].
Parabiosis attenuates AD‑type pathologies
We investigated whether other AD pathologies could also 
be attenuated in the brain after parabiosis. In comparison 
with control transgenic mice, inflammation was signifi-
cantly attenuated in the brain of pa(3-9mon)Tg mice, as 
reflected by decreased levels of astrocytosis and micro-
gliosis (Fig. 3a–f), and reduced levels of proinflamma-
tory cytokines including TNF-α, IL-1, and IL-6 (Supple-
mental Fig. 6). The levels of phosphorylated Tau (pS199 
and pS396), but not total Tau (Tau5), were significantly 
reduced in the brain of pa(3-9mon)Tg mice after parabiosis 
(Fig. 3g–j).
Compared with control transgenic mice, the pa(3-9mon)
Tg mice displayed less neuronal apoptosis and damage as 
reflected by caspase-3 staining in hippocampus (Fig. 4a–d), 
and higher levels of synapse-associated proteins including 
PSD93, PSD95, synapsin-1, and synaptophysin in the brain 
(Fig. 4e, f). These data suggest that neurodegeneration was 
attenuated in the brains of transgenic mice after parabiosis.
Discussion
In the present study, we provide evidence of physiological 
catabolism of brain-derived Aβ in the peripheral system 
in humans and mice. Using this model of parabiosis we, 
for the first time, revealed that the physiological ability of 
Aβ clearance in the periphery has a significant impact on 
preventing Aβ accumulation in the brain, as reflected by 
around 80 % reduction of brain Aβ deposition after para-
biosis. Liver, kidney, gastrointestinal tract and skin are the 
major places for Aβ catabolism in the periphery. The other 
AD-associated pathologies, including tau phosphoryla-
tion, neuroinflammation, and neuronal degeneration, were 
also significantly attenuated in the brains of AD mice after 
parabiosis.
We also found that peripheral clearance of brain-derived 
Aβ exists physiologically. A recent study revealed the efflux 
of brain-derived Aβ to peripheral blood [36]. Consistently, 
we found that the blood Aβ levels in the superior vena cava 
were higher than that in the femoral artery, suggesting that 
Aβ effluxes from the brain into peripheral blood. However, 
the previous study did not address the question of whether 
brain-derived Aβ is catabolized in the peripheral system. 
This information is critical for understanding AD patho-
genesis and development of approaches for prevention and 
treatment of AD. In the present study, we found that blood 
Aβ levels in the inferior vena cava were significantly lower 
than that in the femoral artery in human. This pattern of 
changes was confirmed in APPswe/PS1 mice whose blood 
Aβ levels in jugular vein were higher than that in abdomi-
nal aorta, and blood Aβ levels in posterior vena cava were 
lower than that in abdominal aorta. These findings suggest 
that brain-derived Aβ in the arterial blood is physiologi-
cally cleared when it goes through the capillary bed of the 
peripheral organs and tissues, in particular, liver, kidney, 
gastrointestinal tract, and skin.
The parabiosis model was used to test the efficacy of 
natural peripheral Aβ clearance in removing brain Aβ in 
AD mice. After parabiosis, the circulations of the parabi-
otic mice were connected, and thus Aβ species in the blood 
of the parabiotic AD mice could be transported to the wild-
type mice for clearance. Parabiosis provides parabiotic 
AD mice an additional set of peripheral tissues and organs 
from wild-type mice. As such it is a reliable model to test 
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the efficacy of peripheral Aβ clearance. After parabiosis, 
brain Aβ plaques of AD mice were dramatically reduced 
by around 80 %. It is unlikely that changes in Aβ produc-
tion, degradation, or transport across BBB play dominant 
roles in the reduction of brain Aβ of the parabiotic AD 
mice, as there were no significant changes in the expres-
sion of APPfl, CTF-α, CTF-β, BACE1, IDE, NEP, LRP-1, 
and RAGE. A recent study shows that parabiosis between 
Fig. 2  Parabiosis reduces brain amyloid burden of AD mice. a, c 
Representative images of Congo red and 6E10 immunohistochemical 
staining in neocortex and hippocampus in 9mon Tg and pa(3-9mon) 
Tg mice. Insets show the representative morphology at higher mag-
nification. Scale bars 500 μm. b, d Comparison of the area fraction 
and density of Congo red or 6E10-positive Aβ plaques in the neocor-
tex (Neoco.) and hippocampus (Hippo.) between 9mon Tg and pa(3-
9mon) Tg mice. e, f, g Comparison of Aβ40, Aβ42 and total Aβ levels 
measured with ELISA in TBS, 2 % SDS and 70 % formic acid frac-
tions of brain extracts between 9mon Tg and pa(3-9mon) Tg mice. 
h Illustration of Cerebral amyloid angiopathy (CAA) by immunofluo-
rescence with the antibody to Aβ (6E10) and smooth muscle in the 
vessel wall (1A4). The arrow indicates the Aβ plaques in the brain 
parenchyma near the CAA. Scale bars 100 μm. i CAA visualized 
using Congo red staining. Insets show the representative morphol-
ogy of CAA stained by Congo red at higher magnification. Scale bars 
500 μm. j Comparison of numbers of CAA profiles and area fraction 
of CAA between 9mon Tg and pa(3-9mon) Tg mice. n = 8 per group, 
mean ± SEM, 2-tailed t test, *P < 0.05, **P < 0.01
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Fig. 3  Parabiosis attenuates neuroinflammation and Tau phosphoryl-
ation. a Representative images of astrocytosis stained with anti-GFAP 
antibody in the brain. Insets show the representative morphology at 
higher magnification. Scale bars 500 μm. b Immunofluorescence 
image of amyloid deposition and astrocytosis co-stained with 6E10 
(green) and anti-GFAP (red) antibodies. Aβ plaques were surrounded 
by activated astrocytes. Scale bars 100 μm. c Representative images 
of microgliosis stained with anti-CD45 antibody in the brain. Insets 
show the representative morphology at higher magnification. Scale 
bars 500 μm. d Immunofluorescence image of amyloid deposition 
and microgliosis co-stained with 6E10 and anti-CD45 antibodies. Aβ 
plaques were surrounded by activated microglia. Scale bars 50 μm. e, 
f Comparisons of area fraction and cell density of astrocytosis (e) and 
microgliosis (f) in the neocortex (Neoco.) and hippocampus (Hippo.) 
among pa(3-9mon)Tg mice, control Tg mice and Wt mice. g Repre-
sentative images of intracellular Tau phosphorylation stained with 
anti-pSer396 antibody in the brain. Insets show the representative 
morphology at higher magnification. Scale bars 500 μm. h Western 
blot assays of phosphorylated Tau at multiple sites including pSer199, 
pSer396, and total Tau (Tau5) in the brain homogenates of parabiotic 
Tg mice (PaTg), control Tg mice and wild-type mice (Wt). i Com-
parisons of area fraction and cell density of cells containing phos-
phorylated Tau stained with anti-pSer396 antibody in the neocortex 
among parabiotic Tg mice (PaTg), control Tg mice and wild-type 
mice. j Comparison of band density for phosphorylated Tau (pS199 
and pS396) and total Tau (Tau5) shown in h among pa(3-9mon)Tg 
mice, control Tg mice and Wt mice. n = 8 per group, mean ± SEM., 
one-way ANOVA and Tukey’s test, *P < 0.05, **P < 0.01. N.S. no 
statistical significance
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APPswe/PS1 mouse with ApoE gene and APPswe/PS1 
mouse without ApoE gene did not reduce compact plaque 
burden in the brain of APPswe/PS1 mice with the ApoE 
gene [31]; suggesting that the systematic inflammation 
or immune responses induced by the parabiosis surgery 
would not be responsible for the large reduction of brain 
Aβ burden observed in the present study. In addition, both 
acute and chronic systematic inflammation are suggested to 
accelerate but not halt Aβ deposition and disease progress 
of AD [13, 14, 19]. Moreover, we found that human Aβ 
generated from the parabiotic AD mice can be detected in 
the blood of the parabiotic wild-type mice, indicating that 
Aβ from the AD mice entered the circulation of the parabi-
otic wild-type mice. These findings suggest that parabiosis 
reduces brain Aβ burden through the clearance by periph-
eral tissues and organs, rather than through modulation of 
brain Aβ production, degradation, receptor-mediated trans-
port across the BBB, or systematic inflammation induced 
by the surgery.
The present study reveals the importance of natural 
Aβ catabolic capacity of the peripheral system in clearing 
brain Aβ. Based on the above findings, we can calculate 
Fig. 4  Parabiosis alleviates 
neuronal degeneration and 
loss in the hippocampus of 
pa(3-9mon)Tg mice. a Rep-
resentative images of neurons 
and dendrites at CA1 region 
of hippocampus stained with 
anti-NeuN and anti-MAP-2 
immunofluorescence in pa(3-
9mon)Tg mice, control Tg 
mice, and wild-type (Wt) mice. 
Scale bars 100 μm. b Com-
parison of the area fractions 
of NeuN and MAP-2 staining 
among pa(3-9mon)Tg mice, 
control Tg mice, and Wt mice. c 
Comparison of area fractions of 
caspase-3 staining among pa(3-
9mon)Tg mice, control Tg mice, 
and Wt mice. d Representative 
images of neuronal apoptosis at 
CA3 region of hippocampus as 
stained with activated caspase-3 
immunofluorescence. Scale 
bars 100 μm. e Western blot 
assays of synapse-associated 
proteins including PSD93, 
PSD95, synapsin1 (SYN-1), 
and synaptophysin (Synap.) in 
brain homogenates of pa(3-
9mon)Tg mice, control Tg 
mice, and wild-type (Wt) mice. 
f Comparisons of band density 
of PSD93, PSD95, SYN-1, 
and Synap. among pa(3-9mon)
Tg mice, control Tg mice, 
and wild-type mice. n = 8 per 
group, mean ± SEM, one-way 
ANOVA and Tukey’s test, 
*P < 0.05, **P < 0.01
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the percentage of brain Aβ clearance by a singular periph-
eral system. We define the brain Aβ burden of an AD 
mouse as 100 % and the reduction of brain Aβ by adding 
an additional peripheral system as 68 % of the brain Aβ 
burden of the AD mice as indicated in our study. Accord-
ingly, the total Aβ in the brain of the AD mice should be 
100 % + 100 % × 68 %. Thus, a singular peripheral sys-
tem can remove 40.4 % of Aβ burden in the brain as derived 
from the equation: clearance rate of a singular peripheral 
system = % reduction of brain Aβ in parabiotic AD mice/
[100 % + % reduction of brain Aβ in parabiotic AD mice]. 
This calculation is close to the estimation that efflux of Aβ 
to peripheral blood accounts for 50 % of total brain Aβ 
clearance in humans [36], suggesting that the physiological 
Aβ clearance capacity of the peripheral system provides an 
important mechanism against Aβ accumulation in the brain.
Our findings also imply that dysfunction of periph-
eral Aβ clearance may contribute to the development of 
AD. Indeed, a previous study showed that moderate renal 
impairment is associated with the increased risk for devel-
oping dementia [38]. We also found that the levels of Aβ 
in blood are higher in patients with renal failure than nor-
mal controls [26]. Recent studies reveal that an allele 
(rs3865444C) of CD33, which attenuates the Aβ internaliza-
tion capacity of monocytes, is associated with the increased 
risk of AD [2, 30]. These findings support the notion that 
peripheral Aβ metabolism is involved in AD pathogenesis.
Clearance of brain Aβ represents a promising anti-Aβ 
therapeutic strategy. Peripheral Aβ clearance is proposed to 
be a safer therapeutic approach for AD [25, 45] as adverse 
effects, such as neuroinflammation, vasogenic edema, 
and microhemorrhage occurred in trials of immunothera-
pies which target Aβ clearance likely due to the entry of 
anti-Aβ antibodies into the brain and cerebral vessel walls 
(see review in [24]). Recently, we found that an antibody 
against N-terminus of Aβ can facilitate the conversion of 
Aβ fibrils into more toxic Aβ oligomers, and then induce 
neuronal death in the brain [23]. This might be a reason for 
the acceleration of brain atrophy after clearance of Aβ by 
antibodies in the AN1792 trials [7]. In addition, the anti-
body against N-terminus of Aβ can cross bind to APP on 
the surface of neurons and promote the generation of Aβ [5, 
20], and binding of autoantibodies to neurons is associated 
with increased level of intracellular Aβ [29]; suggesting 
that antibodies against Aβ or neuronal surface APP mol-
ecule may also increase Aβ production once they enter the 
brain. Taken together, these findings suggest that removal 
of brain Aβ from a peripheral approach might be a safe 
therapeutic way for AD.
Some efforts were made by previous investigations to 
test the therapeutic efficacy of peripheral Aβ clearance for 
AD. Enhancement of Aβ degradation in liver by Withania 
somnifera extracts significantly reduced Aβ levels in the 
brain [37]. Peripheral administration of a single chain anti-
body (scFv) to Aβ is as effective as intracranial administra-
tion of the scFv in reducing brain Aβ burden, but does not 
increase brain levels of soluble Aβ, which has potential to 
form more toxic oligomeric species [46]. However, intra-
venous infusion of antibody solanezumab as a peripheral 
“sink” inducer failed to remove brain Aβ deposits [6]. Also, 
peripheral administration of NEP reduces blood Aβ levels 
but fails to clear Aβ accumulated in the brain [12, 44]. In 
contrast, other studies indicate that continuous peripheral 
expression of NEP gene in skeletal muscle is able to reduce 
brain Aβ burden [9, 21, 22]. A critical reason for these con-
flicting results is that these Aβ clearing agents may also 
enter the brain, directly interact with Aβ, and even prohibit 
brain Aβ clearance under certain circumstances. For exam-
ple, a monoclonal antibody 266, the parental antibody of 
solanezumab, can enter the brain and form the complex 
with soluble Aβ species; thus, retarding the efflux of Aβ 
from the brain into the blood [49]. In addition, NEP also 
catabolizes a variety of substrates other than Aβ; some of 
which (i.e. bradykinin, atrial natriuretic factor) are involved 
in brain Aβ accumulation or transport across BBB [16, 33]. 
Thus, these studies did not take a pure approach of clearing 
Aβ in the periphery. In this regard, reliable methodologies 
are needed to test the efficacy of peripheral Aβ clearance. 
Herein, by using a model of parabiosis to provide AD mice 
with an additional peripheral system, we provide a clear 
answer to the controversial issue that peripheral clearance 
of Aβ is a valid therapeutic approach for AD. Although 
the parabiosis cannot be applied to human for AD therapy, 
enhancement of Aβ catabolism in the periphery such as 
liver, kidney, or gastrointestinal tract would be a potential 
valid approach for developing AD therapy in the future.
The property of a therapeutic agent being able to pen-
etrate the BBB is generally regarded as a prerequisite for 
anti-AD agents. Based on our findings drugs which directly 
act on Aβ in the periphery would have a therapeutic signifi-
cance even though they do not pass through BBB. Indeed, 
a parabiosis study shows that circulating ApoE, which does 
not enter the brain, acts as a peripheral sink to induce net 
efflux of Aβ from the brain [31]. Thus, drug development 
against Aβ in the future can focus on the clearance of Aβ 
from the circulation and might be a promising therapeutic 
approach for AD.
Like other studies using the model of parabiosis [1, 
4, 43], we did not perform behavioral tests to examine 
whether cognition is improved after parabiosis, as separa-
tion of the parabionts causes substantial lesions and stress 
to the animals. But consistent with the reduction in brain 
Aβ burden parabiosis also alleviated the other AD patholo-
gies including tau phosphorylation, neuroinflammation, 
and neurodegeneration. This suggests that Aβ catabolism in 
the periphery is able to generate therapeutic efficacy.
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In conclusion, our study reveals the substantial contri-
bution of the peripheral system to the clearance of brain 
Aβ, providing proof-of-concept evidence that develop-
ment of drugs and therapies for AD could be focused 
on peripheral rather than central Aβ clearance [25]. 
This study also implies that deficits in the Aβ clearance 
of the peripheral system might also contribute to AD 
pathogenesis.
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